MDGL - Madrigal Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MDGL is currently covered by 12 analysts with an average price target of $369.56. This is a potential upside of $86.7 (30.65%) from yesterday's end of day stock price of $282.86.

Madrigal Pharmaceuticals's activity chart (see below) currently has 140 price targets and 132 ratings on display. The stock rating distribution of MDGL is 86.67% BUY, 11.11% HOLD and 2.22% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 74.61% with an average time for these price targets to be met of 386.69 days.

Highest price target for MDGL is $460, Lowest price target is $392, average price target is $422.91.

Most recent stock forecast was given by MAYANK MAMTANI from B. RILEY on 01-May-2025. First documented stock forecast 28-Oct-2014.

Currently out of the existing stock ratings of MDGL, 39 are a BUY (86.67%), 5 are a HOLD (11.11%), 1 are a SELL (2.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$460

$165.36 (56.12%)

$422

13 days ago
(01-May-2025)

10/14 (71.43%)

$144.52 (45.81%)

261

Buy

$420

$125.36 (42.55%)

$377

13 days ago
(01-May-2025)

11/13 (84.62%)

$104.52 (33.13%)

421

Buy

$443

$148.36 (50.35%)

$427

21 days ago
(23-Apr-2025)

5/13 (38.46%)

$123.07 (38.47%)

230

Buy

$405

$110.36 (37.46%)

$400

2 months 18 days ago
(26-Feb-2025)

14/18 (77.78%)

$49.12 (13.80%)

286

Buy

$392

$97.36 (33.04%)

$360

4 months 2 days ago
(12-Jan-2025)

5/7 (71.43%)

$88.29 (29.07%)

308

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MDGL (Madrigal Pharmaceuticals) average time for price targets to be met?

On average it took 386.69 days on average for the stock forecasts to be realized with a an average price target met ratio 74.61

Which analyst has the current highest performing score on MDGL (Madrigal Pharmaceuticals) with a proven track record?

JONATHAN WOLLEBEN

Which analyst has the most public recommendations on MDGL (Madrigal Pharmaceuticals)?

Jonathan Wolleben works at JMP and has 10 price targets and 8 ratings on MDGL

Which analyst is the currently most bullish on MDGL (Madrigal Pharmaceuticals)?

Andrea Tan with highest potential upside - $270.36

Which analyst is the currently most reserved on MDGL (Madrigal Pharmaceuticals)?

Matthew Luchini with lowest potential downside - -$183.64

Madrigal Pharmaceuticals in the News

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential.In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Nicholas J. Pritzker’s other stock picks with huge upside potential. Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners,...

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

Net Sales: $137.3 million in Q1 2025, up 33% from Q4 2024. Patient Growth: Over 17,000 patients on Rezdiffra by end of Q1 2025, up from 11,800 in Q4 2024. Prescriber Penetration: 70% of 6,000 top target prescribers have prescribed Rezdiffra. R&D Expenses: $44.2 million in Q1 2025, down from $71.2 million in Q1 2024....
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?